Jaguar Health shares surge 14.17% after-hours after securing Australian patent for crofelemer in short bowel syndrome and MVID, citing reduced parenteral support in trials.

Jaguar Health (JAGX) surged 14.17% in after-hours trading following the announcement of a new Australian patent for crofelemer in treating short bowel syndrome, bile acid diarrhea, and post-resection diarrhea. The patent, issued to subsidiary Napo Pharmaceuticals, strengthens global intellectual property protection for the plant-based drug, which showed early clinical data reducing parenteral support needs in pediatric intestinal failure patients by 12–37%. CEO Lisa Conte highlighted the patent’s role in advancing crofelemer’s development for rare pediatric disorders like microvillus inclusion disease (MVID), where no approved treatments exist. The news coincided with published clinical findings from an investigator-initiated UAE trial and ongoing placebo-controlled studies in the U.S., EU, and Middle East, bolstering investor confidence in the drug’s commercial potential and exclusivity advantages under the FDA’s Botanical Guidance.